Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
IBRANCE Quick Finder
The Summary of Product Characteristics (SPC) for IBRANCE (palbociclib), hard capsule or film-coated tablet (75 mg, 100 mg or 125 mg), is available here.
IBRANCE (palbociclib) is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:
in combination with an aromatase inhibitor;
in combination with fulvestrant in women who have received prior endocrine therapy.
In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
To report an adverse event related to the Pfizer-BioNTech COVID-19 vaccines, click the link below:
www.pfizersafetyreporting.com
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please contact Pfizer pharmacovigilance at
[email protected].
You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at
https://signalement.social-sante.gouv.fr